On November 6, Boston Scientific fell 3.3% in Regular Trading, trading at $43.084 per share, with turnover of $20.4119 million.

The latest market-moving backdrop is that, despite Boston Scientific's previously announced $455 million collaboration with Blackstone Life Sciences to co-fund development of the VITALYST heart pump, investors remain more focused on near-term earnings and guidance pressure.

Background details show the company reported third-quarter adjusted EPS of $0.73, above the $0.72 consensus, and revenue of $5.14 billion, also ahead of expectations. However, it lowered full-year adjusted EPS guidance to $3.16 to $3.18 versus a $3.22 market estimate, and said fourth-quarter revenue is expected to fall 1% to 3%. The company had also said an earlier cybersecurity incident disrupted operations and weighed on sales and profit expectations.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)